|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical Research Council, The MRC Centre for Protein Engineering, Cambridge CB2 2QH, United Kingdom
(RECEIVED April 26, 2007; FINAL REVISION May 28, 2007; ACCEPTED May 29, 2007)
| Abstract |
|---|
|
|
|---|
Keywords: VHL; deubiquitination; HDAC6; IMP
| Introduction |
|---|
|
|
|---|
) and targets it for proteasomal degradation (Kaelin Jr. 2007). Both USP33/VDU1 and USP20/VDU2 are ubiquitinated by pVHL, and VDU2 deubiquitinates and stabilizes HIF-1
(Li et al. 2005). USP33/VDU1 and USP20/VDU2 also regulate the supply of active thyroid hormone by deubiquitining type 2 iodothyronine deiodinase (Curcio-Morelli et al. 2003). The N-terminal region of USP33/VDU1 contains a ZnF UBP domain (Seigneurin-Berny et al. 2001; Hook et al. 2002). This protein module is also found in other deubiquitinating enzymes as well as in HDAC6 (Boyault et al. 2006), a microtubule-associated deacetylase involved in the disposal of misfolded proteins, and BRAP2/IMP, an E3 ubiquitin ligase that regulates mitogenic signaling (Matheny et al. 2004). The ZnF UBP domains of USP5, yeast BRAP2/IMP, and HDAC6 have been shown to bind to ubiquitin with high affinity. The structure of a complex between ubiquitin and the ZnF UBP domain of USP5 has been determined (Reyes-Turcu et al. 2006). The domain primarily interacts with the C-terminal diglycine motif of ubiquitin. The majority of ZnF UBP domains, including that of USP33, are predicted to contain three Zn ions. The ZnF UBP domain of HDAC6, which has a pattern of Zn ligands similar to that of the USP33 domain, has been shown to bind three Zn ions. The USP5 domain is atypical in that it only contains one Zn ion. In this article we report the solution structure and ubiquitin binding properties of the ZnF UBP domain from USP33. | Results and Discussion |
|---|
|
|
|---|







secondary structure with all the
-strands antiparallel and in the order
2-
1-
3-
4-
5 (Fig. 1B). The second and third helices pack on to opposite sides of the
-sheet. There are three bound Zn ions. One of these ions (Zn1) is ligated by two cystine residues in the loop between
2 and
1 and by a cystine and a histidine in the loop between
2 and
3. This site is equivalent to the single Zn ion-binding site in the USP5 domain. A second zinc ion (Zn2) is bound by a cystine and a histidine at the N terminus of the domain and by two cystine residues in turn between the final two strands of the sheet. The histidine in this binding site is at the N terminus of a small helix. The third Zn ion (Zn3) is bound by two histidines in
3 and by two cystines in the turn between
1 and
2.
|
|
2 and
3 and
3 and
4 are larger than in the USP33 domain, and the loop between
1 and
2 is shorter. When these regions are excluded, the central 51 residues of the domains can be superimposed with a root mean square deviation of 1.0 Å. The N- and C-terminal regions, however, differ significantly. The USP5 domain lacks the first two helices, probably because it does not have the Zn2 site, which in the USP33 structure anchors these helices to the rest of the domain. Most ZnF UBP domains are predicted to contain this site and are likely to have a structure similar to that of USP33. The region between the Zn2 and Zn1 coordination sites can apparently tolerate large insertions; the UBP22 domain for example has an additional 20 amino acids in this region compared to the USP33 domain. At the C terminus the USP33 domain structure ends after the last strand of the sheet and does not have the additional helix present in the USP5 domain. These differences have a significant effect on the relative orientations of the termini of ZnF UBP domains and could be important in providing alternative ways of positioning the domain with respect to the rest of the protein in which it is situated. In contrast to what has been observed for some other ZnF UBP domains, we could detect no binding to ubiquitin by the USP33 domain. The USP5 domain binds to ubiquitin using residues located in a deep pocket and a loop (Reyes-Turcu et al. 2006). The equivalent loop in the USP33 domain is six residues shorter (Fig. 2). The differences in the length of this loop are unlikely to explain the lack of ubiquitin binding by the USP33 domain, as the ZnF UBP domains of HDAC6 and yeast IMP that do bind to ubiquitin have loops of similar length. Most of the residues in the pocket are conserved or are replaced with similar residues (Fig. 2). The only exception is Arg 221, which is replaced by a glutamate in USP33. The guanidino group of Arg 221 forms two hydrogen bonds with the main-chain carbonyl oxygen of ubiquitin Gly 75. The replacement of this residue with one of an opposite charge that cannot form these interacts is likely to account for the lack of binding by the USP33 domain. The USP20/VDU2 ZnF UBP domain also has a glutamate at this position and probably does not to bind to ubiquitin.
|
| Materials and Methods |
|---|
|
|
|---|
H
, and C
chemical shifts using the program TALOS (Cornilescu et al. 1999). Structures were calculated using the standard torsion angle dynamics-simulated annealing protocol in the program CNS (Brunger et al. 1998). Ubiquitin binding was studied by recording a 2D 1H-15N-HSQC spectrum of 15N-labeled ZF UBP domain after the addition of equimolar amounts of unlabeled ubiquitin.
| Footnotes |
|---|
Article and publication are at http://www.proteinscience.org/cgi/doi/10.1110/ps.072967807.
| References |
|---|
|
|
|---|
Boyault, C., Gilquin, B., Zhang, Y., Rybin, V., Garman, E., Meyer-Klaucke, W., Matthias, P., Muller, C.W., and Khochbin, S. 2006. HDAC6-p97/VCP controlled polyubiquitin chain turnover. EMBO J. 25: 3357–3366.[CrossRef][Medline]
Brunger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S., et al. 1998. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54: 905–921.[CrossRef][Medline]
Clamp, M., Cuff, J., Searle, S.M., and Barton, G.J. 2004. The Jalview Java alignment editor. Bioinformatics 20: 426–427.
Cornilescu, G., Delaglio, F., and Bax, A. 1999. Protein backbone angle restraints from searching a database for chemical shift and sequence homology. J. Biomol. NMR 13: 289–302.[CrossRef][Medline]
Curcio-Morelli, C., Zavacki, A.M., Christofollete, M., Gereben, B., de Freitas, B.C., Harney, J.W., Li, Z., Wu, G., and Bianco, A.C. 2003. Deubiquitination of type 2 iodothyronine deiodinase by von Hippel–Lindau protein-interacting deubiquitinating enzymes regulates thyroid hormone activation. J. Clin. Invest. 112: 189–196.[CrossRef][Medline]
Hershko, A. and Ciechanover, A. 1998. The ubiquitin system. Annu. Rev. Biochem. 67: 425–479.[CrossRef][Medline]
Hook, S.S., Orian, A., Cowley, S.M., and Eisenman, R.N. 2002. Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ domain) and copurifies with deubiquitinating enzymes. Proc. Natl. Acad. Sci. 99: 13425–13430.
Ingvarsdottir, K., Krogan, N.J., Emre, N.C., Wyce, A., Thompson, N.J., Emili, A., Hughes, T.R., Greenblatt, J.F., and Berger, S.L. 2005. H2B ubiquitin protease Ubp8 and Sgf11 constitute a discrete functional module within the Saccharomyces cerevisiae SAGA complex. Mol. Cell. Biol. 25: 1162–1172.
Kaelin Jr, W.G. 2007. The von Hippel–Lindau tumor suppressor protein and clear cell renal carcinoma. Clin. Cancer Res. 13: 680s–684s.
Kraulis, P.J. 1991. Molscript—A program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24: 946–950.[CrossRef]
Li, Z., Na, X., Wang, D., Schoen, S.R., Messing, E.M., and Wu, G. 2002a. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel–Lindau tumor suppressor protein. J. Biol. Chem. 277: 4656–4662.
Li, Z., Wang, D., Na, X., Schoen, S.R., Messing, E.M., and Wu, G. 2002b. Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel–Lindau tumor suppressor. Biochem. Biophys. Res. Commun. 294: 700–709.[CrossRef][Medline]
Li, Z., Wang, D., Messing, E.M., and Wu, G. 2005. VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1
. EMBO Rep. 6: 373–378.[CrossRef][Medline]
Matheny, S.A., Chen, C., Kortum, R.L., Razidlo, G.L., Lewis, R.E., and White, M.A. 2004. Ras regulates assembly of mitogenic signalling complexes through the effector protein IMP. Nature 427: 256–260.[CrossRef][Medline]
Nijman, S.M., Luna-Vargas, M.P., Velds, A., Brummelkamp, T.R., Dirac, A.M., Sixma, T.K., and Bernards, R. 2005. A genomic and functional inventory of deubiquitinating enzymes. Cell 123: 773–786.[CrossRef][Medline]
Reyes-Turcu, F.E., Horton, J.R., Mullally, J.E., Heroux, A., Cheng, X., and Wilkinson, K.D. 2006. The ubiquitin binding domain ZnF UBP recognizes the C-terminal diglycine motif of unanchored ubiquitin. Cell 124: 1197–1208.[CrossRef][Medline]
Seigneurin-Berny, D., Verdel, A., Curtet, S., Lemercier, C., Garin, J., Rousseaux, S., and Khochbin, S. 2001. Identification of components of the murine histone deacetylase 6 complex: Link between acetylation and ubiquitination signaling pathways. Mol. Cell. Biol. 21: 8035–8044.
Wüthrich, K. 1986. NMR of proteins and nucleic acid. John Wiley, New York.
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |